| [1] |
Lopes AO, Marinho P, Medeiros L, et al. Human gammaherpesvirus 8 oncogenes associated with Kaposi's sarcoma[J]. Int J Mol Sci, 2022,23(13):7203. DOI: 10.3390/ijms23137203.
|
| [2] |
中国医师协会皮肤科医师分会, 中国研究型医院学会皮肤科学专业委员会. 中国卡波西肉瘤诊疗专家共识(2023版)[J]. 中华皮肤科杂志, 2023,56(10):899⁃906. DOI: 10.35541/cjd. 20230261.
|
| [3] |
Inan GA, Aral IP, Arslan SA, et al. Palliative treatment of Kaposi sarcoma with radiotherapy: a single center experience[J]. Radiat Oncol J, 2021,39(1):41⁃47. DOI: 10.3857/roj.2020. 00885.
|
| [4] |
Kandaz M, Bahat Z, Guler OC, et al. Radiotherapy in the management of classic Kaposi's sarcoma: a single institution experience from Northeast Turkey[J]. Dermatol Ther, 2018,31(4):e12605. DOI: 10.1111/dth.12605.
|
| [5] |
Tsao MN, Sinclair E, Assaad D, et al. Radiation therapy for the treatment of skin Kaposi sarcoma[J]. Ann Palliat Med, 2016,5(4):298⁃302. DOI: 10.21037/apm.2016.08.03.
|
| [6] |
赵辨. 临床皮肤病学[M]. 2版. 南京: 江苏科学技术出版社,1993,1036⁃1037.
|
| [7] |
Lebbe C, Garbe C, Stratigos AJ, et al. Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)[J]. Eur J Cancer, 2019,114:117⁃127. DOI: 10.1016/j.ejca.2018.12.036.
|
| [8] |
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009,45(2):228⁃247. DOI: 10.1016/j.ejca.2008.10.026.
|
| [9] |
李晔雄.肿瘤放射治疗学(下册)[M]. 5版. 北京: 中国协和医科大学出版社, 2018:1788⁃1790.
|
| [10] |
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)[J]. Int J Radiat Oncol Biol Phys, 1995,31(5):1341⁃1346. DOI: 10.1016/0360⁃3016(95)00060⁃C.
|
| [11] |
Santo B, Ciurlia E, Barba MC, et al. HDR brachytherapy in the treatment of skin Kaposi sarcoma: a mono⁃institutional series[J]. Cancers (Basel), 2026,18(2):0319. DOI: 10.3390/cancers 18020319.
|
| [12] |
Donato V, Guarnaccia R, Dognini J, et al. Radiation therapy in the treatment of HIV⁃related Kaposi's sarcoma[J]. Anticancer Res, 2013,33(5):2153⁃2157.
|
| [13] |
Harrison M, Harrington KJ, Tomlinson DR, et al. Response and cosmetic outcome of two fractionation regimens for AIDS⁃related Kaposi's sarcoma[J]. Radiother Oncol, 1998,46(1):23⁃28. DOI: 10.1016/s0167⁃8140(97)00141⁃2.
|
| [14] |
Vanpouille⁃Box C, Alard A, Aryankalayil MJ, et al. DNA exonuclease Trex1 regulates radiotherapy⁃induced tumour immunogenicity[J]. Nat Commun, 2017,8:15618. DOI: 10.1038/ncomms15618.
|
| [15] |
Paul S, Roy PK. The effect of stochastic fluctuation in radiation dose⁃rate on cell survival following fractionated radiation therapy[J]. Phys Med Biol, 2012,57(6):1561⁃1573. DOI: 10.1088/0031⁃9155/57/6/1561.
|
| [16] |
Wang X, Wang X, Xiang Z, et al. The clinical application of 3D⁃printed boluses in superficial tumor radiotherapy[J]. Front Oncol, 2021,11:698773. DOI: 10.3389/fonc.2021.698773.
|
| [17] |
Park J, Lee JE. Localized radiotherapy for classic Kaposi's sarcoma: an analysis of lesion characteristics and treatment response[J]. Cancers (Basel), 2024,16(18):3194. DOI: 10. 3390/cancers16183194.
|
| [18] |
Quéro L, Palich R, Valantin MA, et al. The role of radiotherapy in treating Kaposi's sarcoma in HIV infected patients[J]. Cancers (Basel), 2022,14(8):1915. DOI: 10.3390/cancers140 81915.
|